Sipjeondaebo-tang in patients with cancer with anorexia: a protocol for a pilot, randomised, controlled trial

Chunhoo Cheon, Sunju Park, Yu Lee Park, Ching-Wen Huang, Youme Ko, Bo-Hyoung Jang, Yong-Cheol Shin, Seong-Gyu Ko, Chunhoo Cheon, Sunju Park, Yu Lee Park, Ching-Wen Huang, Youme Ko, Bo-Hyoung Jang, Yong-Cheol Shin, Seong-Gyu Ko

Abstract

Introduction: Cancer-related anorexia is the loss of appetite or desire to eat in patients with cancer. Although treatments for cancer-related anorexia do exist, patients have sought complementary and alternative medicine including herbal remedies, due to safety concerns. Sipjeondaebo-tang is one among other popular herbal medicines that are beneficial to management of anorexia in Korea. The purpose of this study is to examine the feasibility for a full randomised clinical trial of Sipjeondaebo-tang for cancer-related anorexia.

Methods and analysis: This study is a randomised, double-blinded and placebo-controlled trial of Sipjeondaebo-tang. For the study, 40 patients with cancer, aged 20-80 years, who reported anorexia, will be recruited. The participants will receive either 3 g of Sipjeondaebo-tang or a placebo, 3 times a day for 4 weeks. The primary end point is a change in the anorexia/cachexia subscale (A/CS) of Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary end points include changes in the visual analogue scale (VAS) of appetite, cortisol and ghrelin. The outcomes will be measured on every visit. Each participant will visit once a week during 4 weeks.

Ethics and dissemination: The present study has been approved by the Institutional Review Board of the Dunsan Korean Medicine Hospital of Daejeon University (reference DJDSKH-15-03-2 (V.2.0)). The results will be disseminated in a peer-reviewed journal and scientific conference.

Trial registration number: NCT02468141; Pre-results.

Keywords: COMPLEMENTARY MEDICINE.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Study flow chart. SJDBT, Sipjeondaebo-tang.

References

    1. Fearon K, Strasser F, Anker SD et al. . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–95. 10.1016/S1470-2045(10)70218-7
    1. Bruera E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 1992;49(Suppl 2):35–42. 10.1159/000227126
    1. Dewys WD, Begg C, Lavin PT et al. . Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491–7.
    1. Del Fabbro E. Current and future care of patients with the cancer anorexia-cachexia syndrome. Am Soc Clin Oncol Educ Book 2015;35:e229–37. 10.14694/EdBook_AM.2015.35.e229
    1. Yavuzsen T, Davis MP, Walsh D et al. . Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005;23:8500–11. 10.1200/JCO.2005.01.8010
    1. Cheng KC, Li YX, Cheng JT. The use of herbal medicine in cancer-related anorexia/ cachexia treatment around the world. Curr Pharm Des 2012;18:4819–26. 10.2174/138161212803216979
    1. Takeda H, Sadakane C, Hattori T et al. . Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 2008;134:2004–13. 10.1053/j.gastro.2008.02.078
    1. Lee JJ, Lee JJ. A phase II study of an herbal decoction that includes Astragali Radix for cancer-associated anorexia in patients with advanced cancer. Integr Cancer Ther 2010;9:24–31. 10.1177/1534735409359180
    1. Choi YK, Jung KY, Woo SM et al. . Effect of Sipjeondaebo-tang on cancer-induced anorexia and cachexia in CT-26 tumor-bearing mice. Mediators Inflamm 2014;2014:736563 10.1155/2014/736563
    1. Korea Food and Drug Administration (KFDA). Research on intake of Chinese medicine by Korean. KFDA; 2007:36–9.
    1. Park SG, Kim YK, Oh MS. Korean medicine prescription. Younglim Publisher, 2003.
    1. KPIC. Korea Pharmaceutical Information Center. Secondary Korea Pharmaceutical Information Center, 2000.
    1. Jeon WY, Shin IS, Shin HK et al. . Gastroprotective effect of the traditional herbal medicine, Sipjeondaebo-tang water extract, against ethanol-induced gastric mucosal injury. BMC Complement Altern Med 2014;14:373 10.1186/1472-6882-14-373
    1. Oh S, Cheon C, Park S et al. . The analysis of the recent research trend of Sipjeondabo-tang in Korea. J Soc Prev Korean Med 2014;18:113–23.
    1. MFDS. MFDS portal site ezdrug 2001. (accessed 3 Jul 2015).
    1. Kim T, Kim HU, Song HJ. A case of gastric emphysema in anorexia nervosa presenting as acute gastric distension. Korean J Gastroenterol 2012;60:315–19. 10.4166/kjg.2012.60.5.315
    1. Park JH, Lee TH, Cheon SL et al. . Severe acute liver and pancreas damage in anorexia nervosa. Korean J Gastroenterol 2009;54:257–60. 10.4166/kjg.2009.54.4.257
    1. FACIT. 2010. (accessed 8 Jul 2015).
    1. Katsutoshi T. Kampo: Japanese-oriental medicine: insights from clinical cases. K.K. Standard McIntyre, 1993.
    1. Lee EH, Chun M, Kang S et al. . Validation of the Functional Assessment of Cancer Therapy-General (FACT-G) scale for measuring the health-related quality of life in Korean women with breast cancer. Jpn J Clin Oncol 2004;34:393–9. 10.1093/jjco/hyh070
    1. Katsutoshi T. East-west medical science learning from the case. Koonja, 2005.
    1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Secondary GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012, 2012.
    1. National Cancer Center. Cancer Facts & Figures 2014. Ministry of Health & Welfare, 2014:18–27.
    1. Global Industry Analysts Inc. Alternative medicine. USA: Global Industry Analysts, Inc., 2012.
    1. Lam W, Jiang Z, Guan F et al. . The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018). BMC Complement Altern Med 2014;14:490 10.1186/1472-6882-14-490
    1. Saif MW, Li J, Lamb L et al. . First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2014;73:373–80.
    1. Kishida Y, Nishii T, Inoue T et al. . Juzentaihoto (TJ-48), a traditional Japanese herbal medicine, influences hemoglobin recovery during preoperative autologous blood donation and after hip surgery. Int J Clin Pharmacol Ther 2009;47:716–21.
    1. Nakamoto H, Mimura T, Honda N. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis. Hemodial Int 2008;12(Suppl 2):S9–14.
    1. Li C, Yang G, Yu M et al. . Effects of traditional Chinese medicine Shu Gan Jian Pi granules on patients with breast cancer and cancer-related fatigue: study protocol for a randomized controlled trial. Trials 2015;16:2261 10.1186/s13063-015-0723-0
    1. Yang XB, Wu WY, Long SQ et al. . Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. Trials 2015;16:11 10.1186/s13063-015-0685-2
    1. Lo LC, Chen CY, Chen ST et al. . Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial. Trials 2012;3232 10.1186/1745-6215-13-232

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa